CytoSorbents Q4 product rev $9.2M (+25% YoY); FY rev $35.6M (+15%); expects FDA decision 2025

Cytosorbents Corp

2025-Q1 EPS reported -$0.02 revenue$8,727,238

Q4 product revenue $9.2M (+25% YoY); product gross margin 71%; operating loss improved 61% to $3.7M.
Adjusted net loss improved 78% to $1.7M ($0.03 per share) vs $7.8M loss in Q4 2023.
Full year product revenue $35.6M (+15%); net loss $20.7M ($0.38 per share); adjusted net loss $12.7M ($0.23 per share).
Cash $9.8M at Dec 31; pro forma $17M after $7.3M rights offering net proceeds.
Expects DrugSorb-ATR FDA & Health Canada decisions in 2025; Q1 2025 product sales to decline due to Germany restructure.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.